European Journal of Internal Medicine
Volume 17, Issue 7 , Pages 505-507 , November 2006

Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment

  • A. Klepfish

      Affiliations

    • Hematology Institute, Wolfson Medical Centre, Tel Aviv and Sackler Medical School, Jerusalem, Israel
    • ,
  • E. Rachmilevitch

      Affiliations

    • Hematology Institute, Wolfson Medical Centre, Tel Aviv and Sackler Medical School, Jerusalem, Israel
    • ,
  • A. Schattner

      Affiliations

    • Department of Medicine, Kaplan Medical Center, Rehovot 76100 and Hebrew University Hadassah Medical School, Jerusalem, Israel
    • Corresponding Author InformationCorresponding author. Fax: +972 8 9441 719.

Received 24 January 2006 ,Revised 23 April 2006 ,Accepted 11 May 2006.

References 

  1. von Schilling C. Immunotherapy with anti-CD20 compounds. Semin Cancer Biol. 2003;13:211–222
  2. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol. 2004;77:303–310
  3. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121:913–918
  4. Otrock ZK, Mahfouzd RA, Oghlakian GO, Salem ZM, Bazarbachi A. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica. 2005;90Suppl:ECR23
  5. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood. 2000;96:1184–1186
  6. Brown KE. Parvovirus B19. In:  Mandell GL,  Bennet JE,  Dolin R editor. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 5th ed.. Churchill Livingstone; 2000;p. 1685–1693

PII: S0953-6205(06)00190-7

doi: 10.1016/j.ejim.2006.05.002

European Journal of Internal Medicine
Volume 17, Issue 7 , Pages 505-507 , November 2006

Article Tools